Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma

Trial Profile

Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Ten Year Follow-up results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 02 Aug 2012 Results have been published in the Journal of Clinical Oncology according to a Spectrum Pharmaceuticals media release. Results were also summarised in the media release.
    • 02 Aug 2012 Primary endpoint 'Time-to-treatment-failure' has been met according to a Spectrum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top